These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-000276-40 A RANDOMISED, OPEN TWO WAY CROSS-OVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW SALBUTAMOL-HFA 134a FORMULATION GIVEN AS CUMULATIVE DOSES AND A REFERENCE SALBUTAMOL-HFA 134a FORMULATION... not-yet-due
Ongoing 2005-004744-32 A CUMULATIVE DOSE RESPONSE STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE OF A NEW SALMETEROL INHALATION AEROSOL CONTAINING A REPLACEMENT HFA PROPELLANT IN A PRESSURISED METERED DOSE INHALER AND EXIST... not-yet-due
Not reported 2005-006076-35 A MULTICENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL-GROUP STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE BETWEEN FLUTICASONE PROPIONATE, 125 OR 250 µg TWICE DAILY DELIVERED VIA pMDI (MERCK... 2007-07-19 due-trials
Not reported 2005-006077-27 A MULTICENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL-GROUP STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE BETWEEN FLUTICASONE PROPIONATE, 100 µg TWICE DAILY DELIVERED VIA A PRESSURISED METE... 2007-07-02 due-trials
Not reported 2005-006078-84 A two-way crossover, sequential-dose, double-blinded, double-dummy, multiple dose, pharmacodynamic, comparative study of fluticasone propionate, 500 μg and 1000 μg twice daily delivered via pressuriz... 2008-07-29 due-trials
Not reported 2007-001743-21 A PHASE II DOUBLE BLIND MODIFIED CROSS OVER DESIGN STUDY EVALUATING THE EFFICACY AND SAFETY OF TRIMETAZIDINE (GENERICS UK LIMITED) AND PLACEBO IN THE TREATMENT OF FIBROMYALGIA 2007-11-02 due-trials

Related organisations

Over time organisations can merge, or split.

We think Merck Generics is now effectively part of Viatris.